The decision by CVS could open the door for more people to prevent unintended pregnancies without a prescription.
A competition probe into Britain's veterinary market is unlikely to hit CVS Group (AIM:CVSG) PLC and Pets at Home Group PLC (LSE:PETS) as hard as feared, analysts have reassured. The Competition and M
CVS Health (CVS) closed the most recent trading day at $74.60, moving +1.06% from the previous trading session.

Why CVS Health Stock Could Stage a Rebound

02:30pm, Wednesday, 03'rd Apr 2024
Health insurance stocks slid yesterday, after final Medicare Advantage (MA) payment rates fell below expectations.
Zacks Retail-Pharmacies and Drug Stores industry players like CVS and WBA are likely to gain despite reimbursement challenges that are hurting the overall health industry. HLF might face the wrath of
Humana, CVS, and UnitedHealth all fell after the CMS approved a 3.7% payment rate increase for Medicare Advantage plans for 2025. "Core" payments are actually expected to decline slightly after accoun
CNBC's Bertha Coombs reports on what's driving health insurer stocks lower.
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The rate adds more pressure on insurers already grappling with high medical costs and uncertainty after the cyberattack on UnitedHealth Group's tech unit.
Higher costs and lower hikes in rates can lead to lower profit growth, which concerns investors.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Three well-known companies stand out among the market's complexity as excellent opportunities for investors looking for significant gains. Each company operates in the broad domains of pharmaceuticals
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Some large health insurers in the U.S. will start covering Wegovy, which has become a popular anti-obesity drug — but not for those using it to lose weight, according to a report by The Wall Street
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE